Right, and part of that guideline review process is branching out into an area that seems to be somewhat extraneous to your mandate and has to do with generics.
I'd like to know why, if your main mandate is to deal with patented medicines, two of the eight hearings you've set up on guidelines on excessive pricing are devoted to generics.